DSM Pharmaceutical Products
has signed a non-exclusive license agreement with Amgen
providing access to its XD high cell density process patents. XD technology is a highly intensified cell culture process with typical titer achievement of 8-to-10 times higher than current standard biomanufacturing processes, according to the company. It is applicable for multiple biological products including proteins, fusion proteins and antibodies, as well as the full spectrum of mammalian cell systems. Financial terms were not disclosed.
Karen King, president of DSM Biologics, said, “We are pleased to enter into this license agreement with Amgen, a global leader in biopharmaceutical drug development and manufacturing. We believe our proprietary XD technology will play an important role in the next generation of biopharmaceutical manufacturing."